Claims for Patent: 10,716,794

Summary for Patent: 10,716,794

Title:	High-strength testosterone undecanoate compositions
Abstract:	The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C.sub.max to serum testosterone C.sub.ave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration C.sub.ave range for a male subject is provided.
Inventor(s):	Giliyar; Chandrashekar (Plymouth, MN), Chickmath; Basawaraj (Minneapolis, MN), Chidambaram; Nachiappan (Sandy, UT), Patel; Mahesh V. (Salt Lake City, UT), Venkateshwaran; Srinivansan (Salt Lake City, UT)
Assignee:	Lipocine Inc. (Salt Lake City, UT)
Application Number:	15/961,691
Patent Claims:	1. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone, said method comprising: orally administering once in the morning and once in the evening, to a male identified as having a morning serum testosterone level of less than 300 ng/dL, a daily dosing regimen of a pharmaceutical composition comprising about 14 weight % (wt %) to about 35 wt % testosterone undecanoate and a carrier, that provides from 430 mg to 460 mg of testosterone undecanoate, to said male per day to provide a serum testosterone Cave in said male in the range of from about 300-1100 ng/dL. 2. The method of claim 1 wherein said carrier comprises a solubilizer and a dispersant. 3. The method of claim 1 wherein said carrier comprises a solidifying agent. 4. The method of claim 1 wherein said carrier comprises a monoglyceride. 5. The method of claim 1 wherein said carrier comprises a diglyceride. 6. The method of claim 1 wherein said carrier comprises a triglyceride. 7. The method of claim 1 wherein said carrier comprises a fatty acid. 8. The method of claim 1 wherein said carrier comprises medium chain monoglycerides and diglycerides. 9. The method of claim 1 wherein said carrier comprises a tocopherol. 10. The method of claim 1 wherein said carrier comprises a hydrophilic surfactant. 11. The method of claim 1 wherein said orally administering is with food. 12. The method of claim 1 wherein said pharmaceutical composition is disposed of in a capsule. 13. The method of claim 1 wherein said daily dosing regimen provides about 450 mg of testosterone undecanoate per day. 14. The method of claim 1 wherein said pharmaceutical composition has at least 5% of the testosterone undecanoate not dissolved and at least 35% dissolved in said carrier. 15. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising: orally administering once in the morning and once in the evening, to a male identified as having a morning serum testosterone level of less than 300 ng/dL, a daily dosing regimen of a pharmaceutical composition comprising testosterone undecanoate and a carrier, said composition comprising from 50-86 weight % (wt %) solubilizer, that provides about 430 mg to 460 mg of testosterone undecanoate, to said male-per day to provide a serum testosterone Cave in said male in the range of from about 300-1100 ng/dL. 16. The method of claim 15 wherein said pharmaceutical composition is disposed of in a capsule. 17. The method of claim 15 wherein said orally administering is with food. 18. The method of claim 15 wherein said carrier has one or more of the following: a fatty acid, a monoglyceride, a diglyceride, a triglyceride, and a tocopherol. 19. The method of claim 15 wherein said carrier has a hydrophilic surfactant. 20. The method of claim 15 wherein said carrier has a solidifying agent. 21. The method of claim 13, wherein said about 450 mg of testosterone undecanoate is provided as two unit dosage forms in the morning and two unit dosage forms in the evening. 22. The method of claim 15, wherein said daily dosing regimen provides about 450 mg of testosterone undecanoate per day. 23. A method for replacement therapy in a male having a condition associated with a deficiency or absence of endogenous testosterone said method comprising: orally administering to a male identified as having a morning serum testosterone level of less than 300 ng/dL, twice-a-day with a meal, two unit dosage forms of a pharmaceutical composition comprising testosterone undecanoate and a carrier, that provides about 430 mg to 460 mg of testosterone undecanoate to said male per day to provide a serum testosterone Cave in said male in the range of from about 300-1100 ng/dL. 24. The method of claim 23 wherein said pharmaceutical composition is disposed of in capsule. 25. The method of claim 23 wherein said daily dosing regimen provides about 450 mg of testosterone undecanoate per day. 26. The method of claim 23, said carrier comprising a solubilizer. 27. The method of claim 23, said carrier comprising a dispersant.